Long-term Effectiveness of Non-ablative Er: YAG Laser for Treatment of Stress Urinary Incontinence (SUI)
- Conditions
- Stress Urinary Incontinence
- Registration Number
- NCT04348994
- Lead Sponsor
- Adrian Gaspar
- Brief Summary
Study is designed to assess the long-term clinical effects and safety profile of non-ablative Er:YAG (IncontiLase®) laser treatment, the durability of the results and the optimal treatment regimen for mild-to-severe stages of genuine female stress urinary incontinence (SUI).
- Detailed Description
All patients with urodynamically proven SUI, who have failed/declined conservative therapies will be informed about the study.
They will be invited to attend a screening/baseline visit. At this visit, they will be asked to perform a standardised 1 hour pad test. Their medical history will be checked and they will undergo a clinical and vaginal examination, pregnancy test and dip stick urinalysis. If their 1 hour pad weight is \>2g and they meet all other inclusion / exclusion criteria, they will be eligible for inclusion. They will receive detailed instructions for performing a 24 hour pad test, and will be asked to keep a 3 day voiding diary. They will be given the International Consultation on Incontinence Questionnaire Short Form (ICIQ-UI SF).
Patients will then undergo 3 outpatient treatment visits. The timing of visits will be approximately 1 month apart. At each of their 3 outpatient appointments, they will be asked about any deleterious effects since their last appointment. Patients will receive 3 treatments in total.
Patients will be invited to attend a follow-up visits 3, 6, 12 and 18 months after the 3rd treatment and asked to complete the 1 hour pad test, 24 hour pad test, 3 day voiding diary and ICIQ-SF questionnaire.
At the 18-, 24- and 30-month follow up, they will be given an option to receive additional single session of non-ablative Er:YAG laser treatment. At each visit, and during additional visit after 36 months, they will be asked to complete all of the tests (1 hour pad test, 24 h hour pad test, 3 day voiding diary and ICIQ-UI SF).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 43
- Adult Female, 18 years of age or older
- Clinical and urodynamic study (UDS) diagnosis of Stress Urinary Incontinence
- No significant improvement in urinary incontinence from at least one previous conservative treatment, such as pelvic floor muscle training
- Pre-existing bladder pathology including prior radiation treatment
- Pregnancy
- BMI>35
- Radical pelvic surgery or previous incontinence surgery
- Urinary tract infection or other active infections of urinary tract or bladder
- SUI III (VLPP > 60 cm H2O)
- Any form of pelvic organ prolapse (POP) stage 2 or greater, according to POP-Q
- Diagnosis of urge incontinence
- Diagnosis of collagen disorders eg.benign joint hypermobility / Elhers-Danlos / Marfans etc.
- Incomplete bladder emptying
- Vesicovaginal fistula
- Faecal incontinence
- Unwillingness or inability to complete follow-up schedule
- Unwillingness or inability to give Informed Consent
- Failure to comply with diary requirements during extended baseline period
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Assessment of 1 hour pad weight test Baseline, 3, 6, 12, 18, 24, 30 and 36 months The change in standardised 1 hour pad weight test from baseline to 36 months following treatment schedule.
Assessment of ICIQ-UI SF scores Baseline, 3, 6, 12, 18, 24, 30 and 36 months Change in mean test scores range = 0 - 21; low score = mild symptoms, high score = significant impact on quality of life.
- Secondary Outcome Measures
Name Time Method Change in leakage frequency as assessed by 3 day voiding diary Baseline, 3, 6, 12, 18, 24, 30 and 36 months The change in leakage frequency from baseline to 36 months following treatment schedule.
Change in 24 hour pad weight test Baseline, 3, 6, 12, 18, 24, 30 and 36 months The change in standardised 24 hour pad weight test from baseline to 36 months following treatment schedule.